BioVersys presents latest data on clinical pipeline at ECCMID 2021

Basel, Switzerland. July 6, 2021, 9am CEST

BioVersys presents update on its innovative antimicrobial pipeline with three oral and six poster presentations at ECCMID, July 9-12, 2021

BioVersys AG, a privately owned clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation, announced today, that it will be presenting an update on its clinical pipeline assets BV100 (Acinetobacter baumannii) and BVL-GSK098 (Tuberculosis), and its preclinical asset BV200 (Staphylococcus aureus), at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), taking place on July 9-12, 2021.

The increasing prevalence of antimicrobial resistance is a multifaceted global public health problem, exacerbated by inappropriate use of antibiotics. However, the current lack of effective antibiotics for harmful bacteria such as A. baumannii and Mycobacterium tuberculosis, coupled with a dearth of innovative therapies in clinical development is a frightening situation that jepodizies modern healthcare.

BioVersys is developing novel solutions to tackle both Carbapenem Resistant Acinetobacter baumannii (CRAB) and multi-drug resistant Tuberculosis (MDR-TB) infections and data will be presented on our two clinical projects, and our paradigm-changing anti-virulence approach addressing Methicillin-Resistant Staphylococcus aureus (MRSA), via three oral presentations and six poster presentations.

For more information please click the following link: